# Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

> **NCT04554680** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 5 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** dabrafenib and trametinib

## Key facts

- **NCT ID:** NCT04554680
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2021-12
- **Final completion:** 2022-04
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04554680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04554680, "Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04554680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*